公开(公告)号：JP2012229227A

公开(公告)日：2012-11-22

申请号：JP2012139422

申请日：2012-06-21

Applicant: Abbott Lab ,  アボット・ラボラトリーズAbbott Laboratories

Inventor： BAXTER JEFFREY H ,  MUKERJI PRADIP ,  VOSS ANNE C ,  TISDALE MICHAEL J

IPC: A61K31/19 ,  A23L1/30 ,  A23L2/52 ,  A61K31/198 ,  A61K31/202 ,  A61K31/205 ,  A61K31/365 ,  A61K31/702 ,  A61P1/12 ,  A61P1/16 ,  A61P3/02 ,  A61P11/00 ,  A61P13/12 ,  A61P19/02 ,  A61P29/00 ,  A61P31/00 ,  A61P35/00

CPC classification number: A61K31/19 ,  A61K2300/00

Abstract: PROBLEM TO BE SOLVED: To provide methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss.SOLUTION: Patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ω-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.

Abstract translation: 要解决的问题：提供预防和治疗慢性炎性疾病，癌症和非自愿减肥的方法。

解决方案：患者单独或者与二十碳五烯酸（20：5ω-3），FOS，肉碱及其混合物联合给予HMB。 HMB可以添加到包含富含大的中性氨基酸的氨基氮源的食品中，所述大型中性氨基酸例如亮氨酸，异亮氨酸，缬氨酸，酪氨酸，苏氨酸和苯丙氨酸，并且基本上不含游离氨基酸。 版权所有（C）2013，JPO＆INPIT

公开(公告)号：WO2012092160A3

公开(公告)日：2012-10-26

申请号：PCT/US2011067031

申请日：2011-12-22

Applicant: ABBOTT LAB ,  BUCK RACHAEL ,  CHOW JOMAY ,  LINKE HAWLEY K ,  RANGAVAJLA NAGENDRA ,  BAXTER JEFFREY H ,  DAVIS STEVEN R

Inventor： BUCK RACHAEL ,  CHOW JOMAY ,  LINKE HAWLEY K ,  RANGAVAJLA NAGENDRA ,  BAXTER JEFFREY H ,  DAVIS STEVEN R

IPC: A23L33/00 ,  A61K31/702 ,  A61P1/00 ,  A61P25/00 ,  A61P29/00

CPC classification number: A61K31/702 ,  A23L33/40 ,  A23V2002/00 ,  A23V2200/32 ,  A23V2200/3202 ,  A23V2200/322 ,  A23V2250/28

Abstract: Disclosed are nutritional compositions including human milk oligosaccharides that can be administered to individuals including preterm infants, infants, toddlers, and children for improving gastrointestinal function and tolerance, as well as the growth of beneficial bacteria. Additional suitable methods of using the nutritional compositions including the human milk oligosaccharides are also disclosed.

Abstract translation: 公开了包括可以给予包括早产儿，婴儿，幼儿和儿童在内的个人的人乳寡糖的营养组合物，用于改善胃肠功能和耐受性，以及有益细菌的生长。 还公开了使用包含人乳低聚糖的营养组合物的另外合适的方法。

公开(公告)号：WO9717085A3

公开(公告)日：1997-08-07

申请号：PCT/US9617860

申请日：1996-11-06

Applicant: ABBOTT LAB

Inventor： MUKERJI PRADIP ,  THURMOND JENNIFER M ,  HANSSON LENNART ,  BAXTER JEFFREY H ,  HARDS ROBERT G ,  LEONARD AMANDA EUN-YEONG ,  ANDERSON STEVEN N ,  HARVEY LINDA A

IPC: C12N15/09 ,  A23L1/305 ,  A61K31/00 ,  A61K38/00 ,  A61P27/00 ,  A61P27/16 ,  A61P31/00 ,  A61P31/04 ,  C07K14/47 ,  A61K38/17

CPC classification number: C07K14/4732 ,  A23L33/19 ,  A61K38/00

Abstract: A method is provided for inhibiting the attachment of H. influenzae to human cells, such as pharyngeal cells, by contacting the bacilli with phosphorylated recombinant human β-casein that have at least 3 phosphate groups. A product containing phosphorylated recombinant human β-casein may be a liquid enteral nutritional product such as infant formula. The enteral nutritional product may be used for the prevention and treatment of otitis media in infants. The phosphorylated recombinant human β-casein may also be administered as a throat spray or used in nose drops or a spray.

公开(公告)号：WO2013056048A3

公开(公告)日：2013-07-18

申请号：PCT/US2012059954

申请日：2012-10-12

Applicant: ABBOTT LAB ,  CHAPMAN TIMOTHY M ,  DEWILLE NORMANELLA T ,  WEARLY DOUGLAS J ,  BAXTER JEFFREY H ,  LOWE KELLEY J ,  MAZER TERRANCE B

Inventor： CHAPMAN TIMOTHY M ,  DEWILLE NORMANELLA T ,  WEARLY DOUGLAS J ,  BAXTER JEFFREY H ,  LOWE KELLEY J ,  MAZER TERRANCE B

IPC: A23L1/305 ,  A23L2/66 ,  A61K9/00 ,  A61K31/197

CPC classification number: A61K31/197 ,  A23L2/66 ,  A23L33/17 ,  A23L33/175 ,  A23L33/19 ,  A23V2002/00 ,  A61K9/08 ,  A61K31/19 ,  A61K31/198 ,  A61K38/00 ,  A61K2300/00 ,  A23V2200/316 ,  A23V2250/0604 ,  A23V2250/0622 ,  A23V2250/54252

Abstract: Disclosed are nutritional products, and particularly, nutritional liquids, comprising beta-alanine. The nutritional products not only provide benefits for individuals concerned with muscle health and functionality, but can also be administered without the adverse side-effect of paresthesia caused by ingestion of beta-alanine.

Abstract translation: 公开了营养产品，特别是包含β-丙氨酸的营养液。 营养产品不仅为肌肉健康和功能方面的个人提供益处，而且还可以在没有摄取β-丙氨酸引起的感觉异常的副作用的情况下给药。

公开(公告)号：WO2005102301A3

公开(公告)日：2006-10-26

申请号：PCT/US2005007951

申请日：2005-03-14

Applicant: ABBOTT LAB ,  BAXTER JEFFREY H ,  MUKERJI PRADIP ,  VOSS ANNE C ,  TISDALE MICHAEL J

Inventor： BAXTER JEFFREY H ,  MUKERJI PRADIP ,  VOSS ANNE C ,  TISDALE MICHAEL J

IPC: A61K31/19 ,  A61K31/202 ,  A61K31/205 ,  A61K31/702 ,  A61P1/12 ,  A61P1/16 ,  A61P3/02 ,  A61P3/12 ,  A61P11/00 ,  A61P13/12 ,  A61P19/02 ,  A61P31/00 ,  A61P35/00

CPC classification number: A61K31/19 ,  A61K2300/00

Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 w-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and subtantially lacking in free amino acids.

Abstract translation: 本发明涉及预防和治疗慢性炎性疾病，癌症和非自愿减肥的方法。 在本发明的实践中，患者是单独的肠道给药HMB，或者与二十碳五烯酸（20:5w-3），FOS，肉碱及其混合物组合。 可以将HMB加入含有富含大中性氨基酸的氨基氮源如亮氨酸，异亮氨酸，缬氨酸，酪氨酸，苏氨酸和苯丙氨酸并且在游离氨基酸中不足的氨基氮源的食品中。

公开(公告)号：AU2005235133B2

公开(公告)日：2010-06-17

申请号：AU2005235133

申请日：2005-03-14

Applicant: ABBOTT LAB

Inventor： TISDALE MICHAEL J ,  VOSS ANNE C ,  MUKERJI PRADIP ,  BAXTER JEFFREY H

IPC: A61K31/19 ,  A61K31/202 ,  A61K31/205 ,  A61K31/702 ,  A61P1/12 ,  A61P1/16 ,  A61P3/02 ,  A61P3/12 ,  A61P11/00 ,  A61P13/12 ,  A61P19/02 ,  A61P31/00 ,  A61P35/00

Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 omega-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and subtantially lacking in free amino acids.

公开(公告)号：AU2005235133A1

公开(公告)日：2005-11-03

申请号：AU2005235133

申请日：2005-03-14

Applicant: ABBOTT LAB

Inventor： TISDALE MICHAEL J ,  VOSS ANNE C ,  MUKERJI PRADIP ,  BAXTER JEFFREY H

IPC: A61K31/19 ,  A61K31/202 ,  A61K31/205 ,  A61K31/702 ,  A61P1/12 ,  A61P1/16 ,  A61P3/02 ,  A61P11/00 ,  A61P13/12 ,  A61P19/02 ,  A61P31/00 ,  A61P35/00

Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 omega-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and subtantially lacking in free amino acids.

公开(公告)号：MY191538A

公开(公告)日：2022-06-30

申请号：MYPI2017000895

申请日：2011-12-22

Applicant: ABBOTT LAB

Inventor： RANGAVAJLA NAGENDRA ,  BUCK RACHAEL ,  DAVIS STEVEN R ,  CHOW JOMAY ,  LINKE HAWLEY K ,  BAXTER JEFFREY H

IPC: A23L33/00 ,  A61K31/702

Abstract: Disclosed are nutritional compositions including human milk oligosaccharides that can be administered to individuals including preterm infants, infants, toddlers, and children for improving gastrointestinal function and tolerance, as well as the growth of beneficial bacteria. Additional suitable methods of using the nutritional compositions including the human milk oligosaccharides are also disclosed. (Fig.1)

公开(公告)号：NZ539139A

公开(公告)日：2007-11-30

申请号：NZ53913902

申请日：2002-10-08

Applicant: ABBOTT LAB

Inventor： BAXTER JEFFREY H ,  LOPEZ JOSE MARIA ,  RUEDA RICARDO

IPC: A23L1/304 ,  A23L1/305 ,  A23L33/00 ,  A61K31/195 ,  A23L1/29

Abstract: Disclosed is a use of a nutritional liquid comprising N-acetyl-L-glutamine or a nutritionally acceptable salt thereof selected from lithium, sodium, potassium, calcium, magnesium, quaternary ammonia cations and amine cations as the sole source of glutamine for manufacturing a medicament for use in providing glutamine supplementation for treating a critical illness or injury characterized by insufficient glutamine production to meet the body's needs.

公开(公告)号：ECSP066873A

公开(公告)日：2006-11-24

申请号：ECSP066873

申请日：2006-09-22

Applicant: ABBOTT LAB

Inventor： BAXTER JEFFREY H ,  MUKERJI PRADIP ,  VOSS ANNE C ,  TISDALE MICHAEL J

IPC: A61K31/19 ,  A61K31/202 ,  A61K31/205 ,  A61K31/702 ,  A61P1/12 ,  A61P1/16 ,  A61P3/02 ,  A61P11/00 ,  A61P13/12 ,  A61P19/02 ,  A61P31/00 ,  A61P35/00

Abstract: La presente invención tiene relación con los procedimientos para la prevención y tratamiento de enfermedades inflamatorias crónicas, cáncer y pérdida involuntaria de peso. En la práctica de la presente invención, a los pacientes se les administra por vía enteral HMB sólo o alternativamente en combinación con eicosapentanóico (20:5 ?-3), FOS, carnitina y mezclas parecidas.En otra caracterización, la presente invención provee un procedimiento para el tratamiento del enflaquecimiento de un paciente asociado con una enfermedad. El procedimiento comprende la administración al paciente de la composición arriba descrita, que contiene HMB en cantidades suficientes para tratar el desgaste asociado con la enfermedad, en el cual, con la administración del compuesto al paciente se trata el desgaste asociado con la enfermedad. En otra caracterización, la presente invención provee un procedimiento para reducir la tasa de crecimiento del tumor en un paciente. El procedimiento consiste en la administración a un paciente el compuesto arriba descrito, que contiene HMB en cantidad suficiente para reducir la tasa de crecimiento del tumor, en el cual, luego de la administración la tasa de crecimiento del tumor es reducida.En otra caracterización, la presente invención provee un procedimiento para la prevención o tratamiento de la enfermedad en pacientes, reduciendo la regulación de la expresión y/o actividad de la proteína kinasa C, el factor nuclear kappa-B, enzimas que conjugan ubiquitina y componentes de proteasoma 26S. Estos procedimientos consisten en la administración a un paciente de HMB, sales, metabolitos o derivados parecidos. Todavía en otra caracterización, el HMB puede ser agregado a productos alimenticios que contienen una fuente de amino-nitrógeno enriquecida con grandes aminoácidos neutros como la leucina, isoleucina, valina, tirosina, treonina y fenilalanina y sustancialmente carente de aminoácidos libres.